Table 3. Allele and genotype frequencies, Hardy-Weinberg distribution and analysis of covariance of ATG7 V471A in different European populations.
| Country | Allele frequencya | Genotype frequency | Hardy-Weinberg | ANOVAc P-value | |||
| V | A | VV | VA | AA | |||
| Denmark (n = 101) | 0.960 | 0.040 | 0.921 | 0.079 | 0.000 | 1.000 | 0.7797 |
| France (n = 134) | 0.981 | 0.019 | 0.963 | 0.037 | 0.000 | 1.000 | 0.8140 |
| Netherlands (n = 174) | 0.983 | 0.017 | 0.966 | 0.034 | 0.000 | 1.000 | 0.5537 |
| Poland (n = 242) | 0.988 | 0.012 | 0.975 | 0.025 | 0.000 | 1.000 | 0.3862 |
| Spain (n = 168) | 0.970 | 0.030 | 0.940 | 0.060 | 0.000 | 1.000 | 0.1481 |
| UK (n = 347) | 0.970 | 0.030 | 0.939 | 0.061 | 0.000 | 1.000 | 0.2611 |
| Germany (n = 371)b | 0.958 | 0.042 | 0.917 | 0.083 | 0.000 | 1.000 | 0.2988 |
| Italy (n = 327) | 0.946 | 0.054 | 0.893 | 0.107 | 0.000 | 0.6122 | 0.0238* |
Populations with ≥100 examined HD patients are shown; n number of investigated HD patients.
a
Allele frequency of nucleotide substitution in ATG7 is described by V ( = valine) as major allele and A ( = alanine) as rare allele.
b
Compared to the number of investigated patients in the previous study [20] we managed it to re-genotype 25 HD patients of the 1st European HD cohort, which failed during the first genotyping.
c
Analysis of covariance showing the effect of the ATG7 V471A polymorphism on the HD AAO in the respective population.
*
significant effect, the level of significance was set to P = 0.05 and the p-value was adjusted for multiple testing according to Bonferroni correction.